Type 1 diabetes is a chronic disease in which the immune system attacks and destroys insulin-producing beta cells in the pancreas, resulting in high blood levels of glucose. A study published January 4th in Cell Stem Cell demonstrates that a gene therapy approach can lead to the long-term survival of functional beta cells as well as normal blood glucose levels for an extended period of time in mice with diabetes. The researchers used an adeno-associated viral (AAV) vector to deliver to the mouse pancreas two proteins, Pdx1 and MafA, which reprogrammed plentiful alpha cells into functional, insulin-producing beta cells.
“This study is essentially the first description of a clinically translatable, simple single intervention in autoimmune diabetes that leads to normal blood sugars, and importantly with no immunosuppression,” says senior study author George Gittes of the University of Pittsburgh School of Medicine. “A clinical trial in both type 1 and type 2 diabetics in the immediate foreseeable future is quite realistic, given the impressive nature of the reversal of the diabetes, along with the feasibility in patients to do AAV gene therapy.”
Approximately 9% of the world’s adult population has diabetes, which can cause serious health problems such as heart disease, nerve damage, eye problems, and kidney disease. One fundamental goal of diabetes treatment is to preserve and restore functional beta cells, thereby replenishing levels of a hormone called insulin, which moves blood glucose into cells to fuel their energy needs. But in patients with type 1 diabetes, beta-cell replacement therapy is likely doomed to failure because the new cells might fall victim to the same autoimmunity that destroyed the original cells.
A potential solution to this problem is to reprogram other cell types into functional beta-like cells, which can produce insulin but are distinct from beta cells and therefore are not recognized or attacked by the immune system. To explore the feasibility of this approach, Gittes and first author Xiangwei Xiao of the University of Pittsburgh School of Medicine engineered an AAV vector to deliver to the mouse pancreas proteins called Pdx1 and MafA, which support beta cell maturation, proliferation, and function. The goal was to generate functional beta-like cells from pancreatic alpha cells, which may be the ideal source for beta cell replacement. For example, alpha cells are plentiful, resemble beta cells, and are in the correct location, all of which could facilitate reprogramming.
By comparing the gene expression patterns of normal beta cells and insulin-producing cells derived from alpha cells, the researchers confirmed nearly complete cellular reprogramming. This gene therapy approach restored normal blood glucose levels in diabetic mice for an extended period of time, typically around four months, and the new insulin-producing cells derived almost exclusively from alpha cells. Moreover, the strategy successfully generated functional insulin-producing cells from human alpha cells.
“The viral gene therapy appears to create these new insulin-producing cells that are relatively resistant to an autoimmune attack,” Gittes says. “This resistance appears to be due to the fact that these new cells are slightly different from normal insulin cells, but not so different that they do not function well.”
Several features of this approach could facilitate translation to humans. For one, AAV vectors like those used in this study are currently undergoing various gene therapy trials in humans. Moreover, the viral vectors can be delivered directly to the human pancreas through a routinely performed non-surgical endoscopic procedure; however, this procedure can elicit pancreatic inflammation. In addition, no immunosuppression is required, so patients would avoid related side effects such as an increased risk of infection.
However, one major concern was that the mice did eventually return to the diabetic state, suggesting that this treatment would not represent a definitive cure for the disease. “The protection from recurrent diabetes in the mice was not permanent, although some studies would suggest that processes in mice are highly accelerated, so four months in mice might translate to several years in humans,” Gittes says.
Currently, the researchers are testing their approach in primates. “If we are able to show efficacy in non-human primates, we will begin work with the FDA to get approval for the use of this viral gene therapy in diabetic patients, both type 1 and type 2,” Gittes says.
The Latest on: Type 1 diabetes
- Record 169 UK patients a week get diabetes-related amputations on December 16, 2018 at 11:00 pm
About 90% of diabetes patients in the UK have type 2 diabetes, which is linked to people’s lifestyles and obesity. Type 1 diabetes is an autoimmune condition unrelated to weight. The charity urged NHS ... […]
- 1 in 7 people with diabetes test blood sugar too often on December 16, 2018 at 4:05 pm
For more than 29 million Americans with type 2 diabetes, testing their blood sugar is just part of daily life. But a new study suggests that some of them test more often than they need to. Fourteen pe... […]
- Olsen: Celebrating 50 years with diabetes on December 16, 2018 at 3:00 am
I recently joined an exclusive group of people, the 2 percent of those with diabetes, who have actually lived 50 years with Type 1 diabetes. That is something to celebrate. Another reason for me ... […]
- Ask D'Mine: Diabetes Death By Cake? on December 15, 2018 at 3:07 am
Welcome back to our weekly diabetes advice column, Ask D'Mine, hosted by veteran type 1 and diabetes author Wil Dubois in New Mexico. Here, you can ask all the burning questions you may not want to as... […]
- Effect of Elevated Triglycerides on Glycemic Management by Patients with Type 2 Diabetes on December 14, 2018 at 5:45 pm
Type 2 diabetes is becoming increasingly prevalent in the developed ... etc.). Participants were separated into 3 groups based on triglyceride levels (1.7 – 2.29, 2.30 – 3.39, and ≥ 3.40 mmol/L). The ... […]
- Link Between Type 1 Diabetes and Psychiatric Comorbidities in Children on December 14, 2018 at 5:45 pm
Following diabetes diagnosis, children and adolescents have high risk of developing psychiatric condition. Type 1 diabetes has many complications and comorbidities. Childhood and early adolescence is ... […]
- "Happy Diabetic" Chef on Type 2 Diabetes and His Passion for Food on December 14, 2018 at 3:11 am
who’s a great guy and was online for many years at “1 Happy Diabetic” sharing his story about life with type 1 diabetes. We came across each other at one point online, and had a conversation and agree... […]
- Risk for Hospitalization for Heart Failure Greater With Diabetes on December 13, 2018 at 2:00 pm
The researchers found crude incidence rates of heart failure hospitalization were 2.4, 12.4, and 5.6 per 1000 person-years for those without diabetes and those with type 2 and 1 diabetes, respectively ... […]
- Sticker Shock: Transitioning Teens With Type 1 Diabetes Under Medicaid to Adult Care on December 13, 2018 at 10:58 am
As a pediatric endocrinologist, I shepherd patients who are living with diabetes through the many changes that life brings. My clinic schedule is filled with toddlers with hypoglycemic unawareness, tw... […]
- Dr. Matthias von Herrath named world’s leading type 1 diabetes expert on December 12, 2018 at 5:16 pm
Newswise — LA JOLLA, CA—Dr. Matthias von Herrath, M.D., who founded the Type 1 Diabetes Center at La Jolla Institute for Immunology (LJI) has been identified as the world’s top expert in Type 1 Diabet... […]
via Google News and Bing News